Vedolizumab (Entyvio)

Brand names:Entyvio
Medication

What people taking Vedolizumab (Entyvio) report

Every report comes from a Lived member, sent anonymously.

Have you tried Vedolizumab (Entyvio) for Ulcerative Colitis?

NameHow it went

About Vedolizumab (Entyvio)

What It's For

Vedolizumab, sold as Entyvio, is a prescription biologic medicine for adults with moderately to severely active ulcerative colitis or Crohn's disease, the two main forms of inflammatory bowel disease (IBD). Ulcerative colitis inflames the lining of the large intestine, while Crohn's disease can affect any part of the digestive tract. A biologic is a medicine made from living cells, in this case a laboratory-made antibody. Vedolizumab is one of several advanced therapies used when IBD is active enough to disrupt daily life, often after or instead of steroids and older immune-suppressing pills. US gastroenterology guidelines place it among the more effective choices for people starting their first advanced therapy for either condition. It is not approved for children in the US.

How It Works

In IBD, immune cells travel from the bloodstream into the wall of the gut and keep inflammation going. To get there, a group of these cells uses a surface protein called alpha-4-beta-7 integrin, which works like a key that fits a docking site found mainly on blood vessels in the gut. Vedolizumab is an antibody that blocks this key, so fewer of these immune cells can leave the blood and enter the intestinal lining. With less traffic into the gut, inflammation can settle and the lining can heal. Because the target is concentrated on cells headed for the gut, the effect is more focused on the intestine than that of medicines that dampen the immune system throughout the body. It still affects immunity, though, and it does not work for everyone.

Dosage & Administration

Treatment starts with two infusions into a vein, given in a clinic or infusion center at week 0 and week 2. Each infusion takes about 30 minutes, and staff watch for reactions until it is finished. From week 6, there are two ways to continue. One is an infusion every 8 weeks. The other is a 108 mg injection under the skin every 2 weeks, using a prefilled syringe or the Entyvio Pen, which people give themselves (or a caregiver gives) after training. People already doing well on infusions can also switch to injections, taking the first injection in place of the next scheduled infusion. Before the first dose, the care team usually checks for tuberculosis (TB) and brings vaccinations up to date. Live vaccines are generally avoided during treatment unless the benefit clearly outweighs the risk, so it helps to get any needed ones beforehand.

Side Effects

The most common side effects are cold-like symptoms such as a stuffy or sore nose and throat, headache, joint pain, nausea, fever, tiredness, cough and back pain. People using the syringe or pen may also get redness or soreness where they inject. Allergic and infusion reactions are uncommon but can happen with the first dose or a later one, and can start during the dose or up to several hours afterward. Signs include hives, rash, flushing, a racing heartbeat, wheezing or shortness of breath. Tell the care team about any of these right away, and get emergency care for trouble breathing. Someone who has had a serious reaction to vedolizumab should not receive it again. Two rare problems need prompt attention. Liver injury has been reported: call the care team promptly about yellowing of the skin or eyes, dark urine, pain in the upper right abdomen, unusual tiredness or loss of appetite. Progressive multifocal leukoencephalopathy (PML), a rare and serious brain infection seen with some medicines that act on the immune system, has not been ruled out with vedolizumab, though only one case has been reported in a person with several other risk factors. Report new or worsening weakness on one side of the body, clumsiness, vision changes, or confusion and memory problems right away.

Interactions & Warnings

Vedolizumab can make infections more likely, including serious ones and tuberculosis. Treatment is usually not started during an important active infection, and doses are generally held if a serious infection develops. Tell the care team about fever, chills, a persistent cough or other signs of infection, and mention any history of frequent or long-lasting infections before starting. Vedolizumab should not be combined with TNF blockers (medicines that block tumor necrosis factor, an inflammatory signal), such as infliximab (Remicade) or adalimumab (Humira), which are other biologics for IBD, because the combination raises infection risk. It should also not be combined with natalizumab (Tysabri), an antibody for multiple sclerosis and Crohn's disease that works in a similar way, because of the added risk of PML and other infections. Make sure every prescriber knows about vedolizumab before starting a new immune-related treatment. For pregnancy, registry and published data have not reliably shown an increased risk of birth defects or miscarriage, and active IBD itself raises the chance of early delivery and low birth weight. Babies exposed before birth may have some of the medicine in their system, so their doctors should know before giving live vaccines. Small amounts pass into breast milk. Anyone pregnant, planning pregnancy or breastfeeding should plan treatment with the gastroenterologist.

What to Expect

Vedolizumab often works gradually rather than within days. Some people notice fewer bowel movements, less bleeding or less pain within the first several weeks, while others take longer. If there is no sign of benefit by week 14, the medicine is usually stopped and another option tried. For people who respond, the aim is long-term control: in the main ulcerative colitis study, about 42% of people who responded early and stayed on infusions every 8 weeks were in remission at one year, compared with 16% of those switched to a placebo. Treatment generally continues as long as it keeps working, and many people are able to reduce or stop steroids. Follow-up includes regular visits, blood tests and sometimes colonoscopy or imaging to check that the bowel lining is healing, not just that symptoms have eased.

Questions to Ask Your Doctor

  1. 1.Why is vedolizumab a better fit for me than other advanced therapies, given my type of IBD and past treatments?
  2. 2.Should I stay on infusions every 8 weeks or switch to injections at home every 2 weeks?
  3. 3.Which tests and vaccinations do I need before starting, and which vaccines should I avoid during treatment?
  4. 4.How will we judge whether it is working by week 14, and what would we try next if it is not?
  5. 5.How should we manage vedolizumab if I become pregnant or plan to breastfeed?

Last reviewed • Oct 2026

Educational content, not medical advice.